

Nobivac Parvo-C lyofilisaat en suspenseervloeistof voor suspensie voor injectie voor honden

Authorised

- Canine parvovirus, strain 154, Live

Product identification

Medicine name:

Nobivac Parvo-C lyofilisaat en suspenseervloeistof voor suspensie voor injectie voor honden

Active substance:

Canine parvovirus, strain 154, Live

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Canine parvovirus, strain 154, Live

7.00 log10 50% cell culture infectious dose / 1.00 millilitre(s)

Pharmaceutical form:

Lyophilisate for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AD01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Netherlands

Available in:

Netherlands

Package description:

Available only in [Dutch](#)

Available only in [Dutch](#)

Available only in [Dutch](#)

Available only in [Dutch](#)

Available only in [Dutch](#)

Available only in [Dutch](#)

Kartonnen doos met 50 enkelvoudige doses.

Kartonnen doos met 50 enkelvoudige doses.

Kartonnen doos met 50 enkelvoudige doses.

Kartonnen doos met 50 enkelvoudige doses.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Legal basis not covered by Directive 2001/82/EC

Marketing authorisation holder:

Intervet Nederland B.V.

Marketing authorisation date:

18/04/2002

Manufacturing sites for batch release:

Intervet International B.V.

Responsible authority:

Medicines Evaluation Board

Authorisation number:

REG NL 9479

Date of authorisation status change:

10/01/2022

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.